Integrating immunotherapy in the treatment of resectable gastric cancer: Are we on the right track?

Pazo-Cid R; Pons PG

doi:10.1016/j.medj.2024.10.020

← 뒤로

Integrating immunotherapy in the treatment of resectable gastric cancer: Are we on the right track?

Med (New York, N.Y.) 2025 Vol.6(3) p. 100543

Pazo-Cid R, Pons PG

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

📝 환자 설명용 한 줄

Long et al.

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Pazo-Cid R, Pons PG (2025). Integrating immunotherapy in the treatment of resectable gastric cancer: Are we on the right track?. Med (New York, N.Y.), 6(3), 100543. https://doi.org/10.1016/j.medj.2024.10.020

MLA Pazo-Cid R, et al.. "Integrating immunotherapy in the treatment of resectable gastric cancer: Are we on the right track?." Med (New York, N.Y.), vol. 6, no. 3, 2025, pp. 100543.

PMID 40088881

DOI 10.1016/j.medj.2024.10.020

Abstract

Long et al. evaluated neoadjuvant (NAT) cadonilimab plus FLOT chemotherapy (ChT) in locally advanced gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma, showing a pathological complete response (pCR) rate of 21.1% and an R0 resection rate of 100%. These findings align with other perioperative immunotherapy trials, although challenges remain in optimizing event-free survival (EFS).

MeSH Terms

Humans; Stomach Neoplasms; Neoadjuvant Therapy; Immunotherapy; Adenocarcinoma; Esophagogastric Junction; Antineoplastic Combined Chemotherapy Protocols